Contineum Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Contineum Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $473.00K.
- Contineum Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $198.00K, a 725.00% increase year-over-year.
- Contineum Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $173.00K, a 1230.77% increase year-over-year.
- Contineum Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $24.00K, a 80.33% decline year-over-year.
- Contineum Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $219.00K, a 45.93% decline from fiscal 2024.
- Contineum Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $405.00K, a 154.72% increase from fiscal 2023.
- Contineum Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $159.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $473.00K 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $198.00K 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $219.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $173.00K 10-Q · filed 2025-10-30 | |
| 2025-03-31 | $24.00K 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $405.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $13.00K 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $13.00K 10-Q · filed 2025-10-30 | |
| 2024-03-31 | $122.00K 10-Q · filed 2025-10-30 | |
| 2023-12-31 | $159.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $83.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $47.00K 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $8.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |